Squarepoint’s Acrivon Therapeutics ACRV Stock Holding History

Squarepoint’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.2K	Buy	27,472 +1,310	+5%	+$2.29K	﹤0.01%	4157
2025 Q4	$63K	Sell	26,162 -78,162	-75%	-$170K	﹤0.01%	4107
2025 Q3	$189K	Sell	104,324 -48,281	-32%	-$67.9K	﹤0.01%	3965
2025 Q2	$182K	Buy	+152,605	New	+$209K	﹤0.01%	4010
2024 Q3	–	Sell	-17,207	Closed	-$99.8K	–	4051
2024 Q2	$99.8K	Buy	+17,207	New	+$139K	﹤0.01%	3801

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's ACRV Position: Q1 2026 in Review

Squarepoint increased its Acrivon Therapeutics (ACRV) stake by 5% in Q1 2026, buying an estimated $2.29K and bringing the position to 27,472 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

Squarepoint first reported a position in ACRV in Q2 2024 and has held it in 5 quarters since. The position peaked at $189K in Q3 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Squarepoint held 27,472 shares of Acrivon Therapeutics worth $38.2K as of Q1 2026.
Squarepoint bought 1,310 Acrivon Therapeutics shares in Q1 2026, an estimated $2.29K.
Acrivon Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4157 holding.
Squarepoint first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 5 quarters since.
Squarepoint's Acrivon Therapeutics position peaked at $189K in Q3 2025.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.